Aeon Credit Service remains attractive

KUALA LUMPUR: There could be further upside for AEON Credit Service (M) Bhd as its current valuations suggest the market has yet to price in the recovery, says RHB Research.

The group, which remains RHB's top "buy" pick on the recovery theme, beat expectations in 1QFY22 with earnings that came to 58% and 60% of the research house's and consensus full-year estimates.

The positive surprise was owing to about Rm20mil in net write-backs on better collection and improved delinquency movement.

While RHB views this as unsustainable as it does not expect more write-backs in subsequent quarters, the research house raised FY22 earnings by 7% on lower credit cost assumption.

Meanwhile, it lowered FY23 projection by 4% due to less aggressive receivable growth assumption.

The research house raised its target price to RM14.80 on the back of the earnings revisions and some housekeeping updates on valuation input.

Moving forward, Aeon Credit Service expects a tougher situation in 3QFY22 due to the full lockdown.

"Relief measures (eg moratorium) are being considered but will be targeted, hence mitigating profitability impact.

"Collection trend has been healthy despite the re-imposition of MCO 3.0, largely due to various cash handouts and consumer-friendly relief measures by the Government," said RHB.
Article type: metered
User Type: anonymous web
User Status:
Campaign ID: 1
Cxense type: free
User access status: 0
Subscribe now to our Premium Plan for an ad-free and unlimited reading experience!

Next In Business News

Exciting deals at Sunway Theme Parks Mega Roadshow
CPO futures likely to trade in yo-yo mode next week
Maybe Apple’s weakness isn’t just supply chain woes
Good news for the global economy
BP, Chubu Power to study CCS project at Nagoya
Short Position: Private equity exits, Managing cyber threats, Don’t kick the can down the road
Bonds surge as traders call time on hikes
Central banks continue fight against inflation
Defining market manipulation
Lee Chun Fai redesignated as IJM CEO and MD

Others Also Read